A Controlled Trial of Lazabemide (Ro 19-6327) in Levodopa-Treated Parkinson's Disease

A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline Data

“…Individuals with early PD who were either treatment naïve or treated with a MAO-B inhibitor at baseline were, therefore, included in Part 1 of the PASADENA study. The recruited PASADENA study population was also similar to other early PD therapeutic trial populations (56,59,60). In this study, a comparison of the baseline characteristics of PASADENA study participants showed that those who received treatment with MAO-B inhibitors were younger with a longer time from diagnosis compared with the treatment-naïve group; however, the two groups had similar overall symptom severity at baseline.…”

A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline Data

“…Individuals with early PD who were either treatment naïve or treated with a MAO-B inhibitor at baseline were, therefore, included in Part 1 of the PASADENA study. The recruited PASADENA study population was also similar to other early PD therapeutic trial populations (56,59,60). In this study, a comparison of the baseline characteristics of PASADENA study participants showed that those who received treatment with MAO-B inhibitors were younger with a longer time from diagnosis compared with the treatment-naïve group; however, the two groups had similar overall symptom severity at baseline.…”

A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline Data

“…Individuals with early PD who were either treatment naïve or treated with a MAO-B inhibitor at baseline were, therefore, included in Part 1 of the PASADENA study. The recruited PASADENA study population was also similar to other early PD therapeutic trial populations (56,59,60). In this study, a comparison of the baseline characteristics of PASADENA study participants showed that those who received treatment with MAO-B inhibitors were younger with a longer time from diagnosis compared with the treatment-naïve group; however, the two groups had similar overall symptom severity at baseline.…”

A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline Data

“…Individuals with early PD who were either treatment naïve or treated with a MAO-B inhibitor at baseline were, therefore, included in Part 1 of the PASADENA study. The recruited PASADENA study population was also similar to other early PD therapeutic trial populations (56,59,60). In this study, a comparison of the baseline characteristics of PASADENA study participants showed that those who received treatment with MAO-B inhibitors were younger with a longer time from diagnosis compared with the treatment-naïve group; however, the two groups had similar overall symptom severity at baseline.…”